Type of condition | Author (ref) publication year | Type of study | N cancers/N study population | Relative risks of cancer overall (HR, OR, IRR, SIR, 95% CI) |
---|---|---|---|---|
AS/PsA | Burmester 201216 | RCT Median duration of exposure 0.4 years | N cancers not available 1684 patients with AS 837 patients with PsA | SIR AS 0.51 (0.16 to 1.19) PsA 0.68 (0.22 to 1.59) |
PsA/psoriasis | Dommasch 201115 | Meta-analysis Of 20 RCTs Mean duration follow-up 17.8 weeks | N cancer TNFi exposed; 28 Placebo group; 4 /Total 6810 patients 20% PsA, 80% Psoriasis | OR for entire group 1.48 (0.71 to 3.09) |
AS/PsA | Haynes 201218 | Cohort study | N solid cancer TNFi exposed: 6/783 AS 17/1036 PsA TNFi naïve: 11/703 AS 30/1462 PsA | HR AS 0.15 (0.03 to 0.76) PsA 0.88 (0.39 to 1.98) |
AS/PsA | Carmona 201119 | Cohort study | N cancer not available 761 patients with AS 727 patients with PsA | SIR* AS 0.92 (0.44 to 1.70) PsA 0.73 (0.33 to 1.39) |
PsA | Saad 201120 | Cohort study | N cancers TNFi exposed:14/596 PsA TNFi naïve: 67/1115 | IRR 1.0 (0.5 to 2.2) |
AS | van der Heijde 201413 | Pooled analysis from 5 RCTs | N cancer 6/1074 | SIR 1.47 (0.54 to 3.21) |
Search terms used: Psoriatic arthritis, Ankylosing spondylitis, Spondylarthritis+Tumour Necrosis Factor (TNF) inhibitor+cancer, malignancy, co-morbidity; English, 1980–2015.
*Compared with the general population.
AS, ankylosing spondylitis; IRR, incidence rate ratio; PsA, psoriatic arthritis; RCT, randomised clinical trial; SIR, standardised incidence ratio; TNFi, tumour necrosis factor inhibitor.